What impact do Revlimid (lenalidomide) and Pomalyst (pomalidomide) have on the bone marrow?

In this week’s video, Brian G.M. Durie explains that even though Revlimid and Pomalyst may reduce white blood cell counts, they do not permanently affect the bone marrow.

BOTTOM LINE:
Revlimid and Pomalyst may reduce white blood cell counts, so stop or adjust dosing accordingly.

If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected]

To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected]

 

 

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

 

Video
IMF TV Blog Category
Old Id
1515

Source URL: https://www.myeloma.org/videos/impact-do-revlimidr-lenalidomide-pomalystr-pomalidomide-have-bone-marrow